Seagen inks deal with Dutch biotech to develop and commercialize drug candidate

30
Oct
  • Prime healthcare: How Amazon’s $3.9B One Medical deal could boost its subscription program
  • Dr. Anthony Fauci stops in Seattle for Fred Hutch Q&A, throws first pitch at Mariners game
  • Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs
  • Publicly traded biotech company Absci lays off employees, citing ‘macro-economic conditions’
  • Seattle startup HDT Bio lands $1.8M U.S. Army grant to develop nasal spray against viruses

    • Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech firm based mostly in Utrecht, Netherlands. Seagen pays Lava $50 million upfront to completely license Lava-1223, a “bispecific T cell engager” designed to direct sure T cells to tumors through the goal EGFR on most cancers cells. Seagen can even pay Lava as much as $650 million in future milestone funds and has the choice to completely negotiate rights to use Lava’s platform to 2 different tumor targets. The deal, introduced Monday, comes a month after talks over a possible acquisition of Bothell, Wash.-based Seagen by Merck reportedly stalled over the value.

    See also  Seattle biotech company is the first to receive approval to test B cell gene therapy in humans
    Megusta

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Block "video-noi-bat" not found